1. Home
  2. LEXX vs MDRR Comparison

LEXX vs MDRR Comparison

Compare LEXX & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • MDRR
  • Stock Information
  • Founded
  • LEXX 2004
  • MDRR 2015
  • Country
  • LEXX Canada
  • MDRR United States
  • Employees
  • LEXX N/A
  • MDRR N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • MDRR Real Estate Investment Trusts
  • Sector
  • LEXX Health Care
  • MDRR Real Estate
  • Exchange
  • LEXX Nasdaq
  • MDRR Nasdaq
  • Market Cap
  • LEXX 16.5M
  • MDRR 17.1M
  • IPO Year
  • LEXX N/A
  • MDRR 2018
  • Fundamental
  • Price
  • LEXX $1.03
  • MDRR $13.72
  • Analyst Decision
  • LEXX Strong Buy
  • MDRR
  • Analyst Count
  • LEXX 1
  • MDRR 0
  • Target Price
  • LEXX $4.00
  • MDRR N/A
  • AVG Volume (30 Days)
  • LEXX 187.7K
  • MDRR 6.8K
  • Earning Date
  • LEXX 07-14-2025
  • MDRR 08-07-2025
  • Dividend Yield
  • LEXX N/A
  • MDRR 1.97%
  • EPS Growth
  • LEXX N/A
  • MDRR N/A
  • EPS
  • LEXX N/A
  • MDRR N/A
  • Revenue
  • LEXX $615,923.00
  • MDRR $9,649,145.00
  • Revenue This Year
  • LEXX $46.98
  • MDRR N/A
  • Revenue Next Year
  • LEXX $17.26
  • MDRR N/A
  • P/E Ratio
  • LEXX N/A
  • MDRR N/A
  • Revenue Growth
  • LEXX 49.85
  • MDRR N/A
  • 52 Week Low
  • LEXX $0.77
  • MDRR $9.55
  • 52 Week High
  • LEXX $3.72
  • MDRR $15.00
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 63.07
  • MDRR 66.25
  • Support Level
  • LEXX $0.86
  • MDRR $10.24
  • Resistance Level
  • LEXX $1.09
  • MDRR $14.50
  • Average True Range (ATR)
  • LEXX 0.08
  • MDRR 0.58
  • MACD
  • LEXX 0.02
  • MDRR 0.26
  • Stochastic Oscillator
  • LEXX 81.47
  • MDRR 81.69

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About MDRR Medalist Diversified REIT Inc.

Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.

Share on Social Networks: